These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
||||||||||
(State or other jurisdiction of
incorporation or organization) |
(I.R.S. Employer
Identification Number) |
||||||||||
|
|
|
|
||||||||
(Address of principal executive offices) | (Zip Code) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
|
|
|
|
☒ | Accelerated filer |
☐
|
|||||||||||
Non-accelerated filer |
☐
|
Smaller reporting company |
|
|||||||||||
Emerging growth company |
|
Page | ||||||||
Part I. Financial Information | ||||||||
Item 1.
|
||||||||
Item 2.
|
||||||||
Item 3.
|
||||||||
Item 4.
|
||||||||
Part II. Other Information | ||||||||
Item 1.
|
||||||||
Item 1A.
|
||||||||
Item 2.
|
||||||||
Item 5. | ||||||||
Item 6.
|
||||||||
Three Months Ended | |||||||||||||||||||||||
March 31,
2025 |
March 31,
2024 |
||||||||||||||||||||||
Revenues
|
$ |
|
$ |
|
|||||||||||||||||||
Cost of revenues
|
|
|
|||||||||||||||||||||
Sales and marketing |
|
|
|||||||||||||||||||||
Technology and development
|
|
|
|||||||||||||||||||||
General and administrative
|
|
|
|||||||||||||||||||||
Operating income
|
|
|
|||||||||||||||||||||
Other income (expense):
|
|||||||||||||||||||||||
Interest expense
|
(
|
(
|
|||||||||||||||||||||
Interest and other income (expense) |
|
|
|||||||||||||||||||||
Income before income taxes
|
|
|
|||||||||||||||||||||
Provision for income taxes |
(
|
(
|
|||||||||||||||||||||
Net income
|
$ |
|
$ |
|
|||||||||||||||||||
Earnings per share:
|
|||||||||||||||||||||||
Basic
|
$ |
|
$ |
|
|||||||||||||||||||
Diluted
|
$ |
|
$ |
|
|||||||||||||||||||
Weighted-average shares of common stock outstanding:
|
|||||||||||||||||||||||
Basic
|
|
|
|||||||||||||||||||||
Diluted
|
|
|
Three Months Ended | |||||||||||||||||||||||
March 31,
2025 |
March 31,
2024 |
||||||||||||||||||||||
Net income | $ |
|
$ |
|
|||||||||||||||||||
Other comprehensive income (loss): | |||||||||||||||||||||||
Foreign currency translation adjustments, net of income tax benefit of $
|
|
(
|
|||||||||||||||||||||
Net change in unrealized gains (losses) on available-for-sale securities, net of income tax benefit of $
|
(
|
|
|||||||||||||||||||||
Cash flow hedges: | |||||||||||||||||||||||
Net unrealized gains (losses) |
(
|
|
|||||||||||||||||||||
Reclassification of net (gains) losses included in net income |
(
|
|
|||||||||||||||||||||
Net change, net of income tax benefit (expense) of $
|
(
|
|
|||||||||||||||||||||
Fair value hedges: | |||||||||||||||||||||||
Net change in unrealized gains (losses) excluded from the assessment of effectiveness, net of income tax benefit of $
|
(
|
|
|||||||||||||||||||||
Total other comprehensive income (loss) |
(
|
|
|||||||||||||||||||||
Comprehensive income | $ |
|
$ |
|
|
Three Months Ended | ||||||||||||||||||||||
|
March 31,
2025 |
March 31,
2024 |
|||||||||||||||||||||
Cash flows from operating activities: | |||||||||||||||||||||||
Net income | $ |
|
$ |
|
|||||||||||||||||||
Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||||||||||||||
Additions to content assets |
(
|
(
|
|||||||||||||||||||||
Change in content liabilities |
(
|
(
|
|||||||||||||||||||||
Amortization of content assets |
|
|
|||||||||||||||||||||
Depreciation and amortization of property, equipment and intangibles |
|
|
|||||||||||||||||||||
Stock-based compensation expense |
|
|
|||||||||||||||||||||
Foreign currency remeasurement loss (gain) on debt |
|
(
|
|||||||||||||||||||||
Other non-cash items |
|
|
|||||||||||||||||||||
Deferred income taxes |
(
|
(
|
|||||||||||||||||||||
Changes in operating assets and liabilities: | |||||||||||||||||||||||
Other current assets |
(
|
|
|||||||||||||||||||||
Accounts payable |
(
|
(
|
|||||||||||||||||||||
Accrued expenses and other liabilities |
|
|
|||||||||||||||||||||
Deferred revenue |
|
|
|||||||||||||||||||||
Other non-current assets and liabilities |
(
|
(
|
|||||||||||||||||||||
Net cash provided by operating activities |
|
|
|||||||||||||||||||||
Cash flows from investing activities: | |||||||||||||||||||||||
Purchases of property and equipment |
(
|
(
|
|||||||||||||||||||||
Purchases of investments |
(
|
|
|||||||||||||||||||||
Proceeds from maturities and sales of investments |
|
|
|||||||||||||||||||||
Net cash provided by (used in) investing activities |
|
(
|
|||||||||||||||||||||
Cash flows from financing activities: | |||||||||||||||||||||||
Repayments of debt |
(
|
(
|
|||||||||||||||||||||
Proceeds from issuance of common stock |
|
|
|||||||||||||||||||||
Repurchases of common stock |
(
|
(
|
|||||||||||||||||||||
Taxes paid related to net share settlement of equity awards |
(
|
(
|
|||||||||||||||||||||
Other financing activities |
(
|
|
|||||||||||||||||||||
Net cash used in financing activities |
(
|
(
|
|||||||||||||||||||||
Effect of exchange rate changes on cash, cash equivalents and restricted cash |
|
(
|
|||||||||||||||||||||
Net decrease in cash, cash equivalents and restricted cash |
(
|
(
|
|||||||||||||||||||||
Cash, cash equivalents and restricted cash at beginning of period |
|
|
|||||||||||||||||||||
Cash, cash equivalents and restricted cash at end of period | $ |
|
$ |
|
As of | |||||||||||
|
March 31,
2025 |
December 31,
2024 |
|||||||||
(unaudited) | |||||||||||
Assets
|
|||||||||||
Current assets:
|
|||||||||||
Cash and cash equivalents
|
$ |
|
$ |
|
|||||||
Short-term investments |
|
|
|||||||||
Other current assets
|
|
|
|||||||||
Total current assets
|
|
|
|||||||||
Content assets, net
|
|
|
|||||||||
Property and equipment, net
|
|
|
|||||||||
Other non-current assets
|
|
|
|||||||||
Total assets
|
$ |
|
$ |
|
|||||||
Liabilities and Stockholders’ Equity
|
|||||||||||
Current liabilities:
|
|||||||||||
Current content liabilities
|
$ |
|
$ |
|
|||||||
Accounts payable
|
|
|
|||||||||
Accrued expenses and other liabilities
|
|
|
|||||||||
Deferred revenue
|
|
|
|||||||||
Short-term debt
|
|
|
|||||||||
Total current liabilities
|
|
|
|||||||||
Non-current content liabilities
|
|
|
|||||||||
Long-term debt
|
|
|
|||||||||
Other non-current liabilities
|
|
|
|||||||||
Total liabilities
|
|
|
|||||||||
Commitments and contingencies (Note 8)
|
|
|
|||||||||
Stockholders’ equity:
|
|||||||||||
Common stock, $
|
|
|
|||||||||
Treasury stock at cost (
|
(
|
(
|
|||||||||
Accumulated other comprehensive income (loss) |
(
|
|
|||||||||
Retained earnings
|
|
|
|||||||||
Total stockholders’ equity
|
|
|
|||||||||
Total liabilities and stockholders’ equity
|
$ |
|
$ |
|
Three Months Ended | ||||||||||||||||||||||||||
March 31,
2025 |
March 31,
2024 |
|||||||||||||||||||||||||
Total stockholders' equity, beginning balances | $ |
|
$ |
|
||||||||||||||||||||||
Common stock and additional paid-in capital: | ||||||||||||||||||||||||||
Beginning balances
|
$ |
|
$ |
|
||||||||||||||||||||||
Issuance of common stock |
|
|
||||||||||||||||||||||||
Stock-based compensation expense |
|
|
||||||||||||||||||||||||
Ending balances | $ |
|
$ |
|
||||||||||||||||||||||
Treasury stock: | ||||||||||||||||||||||||||
Beginning balances
|
$ |
(
|
$ |
(
|
||||||||||||||||||||||
Repurchases of common stock to be held as treasury stock |
(
|
(
|
||||||||||||||||||||||||
Ending balances | $ |
(
|
$ |
(
|
||||||||||||||||||||||
Accumulated other comprehensive income (loss): | ||||||||||||||||||||||||||
Beginning balances
|
$ |
|
$ |
(
|
||||||||||||||||||||||
Other comprehensive income (loss) |
(
|
|
||||||||||||||||||||||||
Ending balances | $ |
(
|
$ |
(
|
||||||||||||||||||||||
Retained earnings: | ||||||||||||||||||||||||||
Beginning balances | $ |
|
$ |
|
||||||||||||||||||||||
Net income
|
|
|
||||||||||||||||||||||||
Ending balances | $ |
|
$ |
|
||||||||||||||||||||||
Total stockholders' equity, ending balances
|
$ |
|
$ |
|
Three Months Ended | ||||||||||||||||||||||||||
March 31,
2025 |
March 31,
2024 |
|||||||||||||||||||||||||
(in thousands) | ||||||||||||||||||||||||||
United States and Canada (UCAN) | $ |
|
$ |
|
||||||||||||||||||||||
Europe, Middle East, and Africa (EMEA) |
|
|
||||||||||||||||||||||||
Latin America (LATAM) |
|
|
||||||||||||||||||||||||
Asia-Pacific (APAC) |
|
|
||||||||||||||||||||||||
Total Revenues | $ |
|
$ |
|
||||||||||||||||||||||
Three Months Ended | |||||||||||||||||||||||
March 31,
2025 |
March 31,
2024 |
||||||||||||||||||||||
(in thousands, except per share data) | |||||||||||||||||||||||
Basic earnings per share: | |||||||||||||||||||||||
Net income
|
$ |
|
$ |
|
|||||||||||||||||||
Shares used in computation:
|
|||||||||||||||||||||||
Weighted-average shares of common stock outstanding |
|
|
|||||||||||||||||||||
Basic earnings per share | $ |
|
$ |
|
|||||||||||||||||||
Diluted earnings per share: | |||||||||||||||||||||||
Net income
|
$ |
|
$ |
|
|||||||||||||||||||
Shares used in computation:
|
|||||||||||||||||||||||
Weighted-average shares of common stock outstanding |
|
|
|||||||||||||||||||||
Effect of dilutive stock-based awards |
|
|
|||||||||||||||||||||
Weighted-average number of shares |
|
|
|||||||||||||||||||||
Diluted earnings per share | $ |
|
$ |
|
Three Months Ended | |||||||||||||||||||||||
March 31,
2025 |
March 31,
2024 |
||||||||||||||||||||||
(in thousands) | |||||||||||||||||||||||
Stock-based awards |
|
|
As of March 31, 2025 | |||||||||||||||||||||||||||||||||||||||||||||||
Amortized Cost | Gross Unrealized Gains | Gross Unrealized Losses | Estimated Fair Value | Cash and cash equivalents | Short-term investments | Other Current Assets | Non-current Assets | ||||||||||||||||||||||||||||||||||||||||
(in thousands) | |||||||||||||||||||||||||||||||||||||||||||||||
Cash | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||||||||
Level 1 securities: | |||||||||||||||||||||||||||||||||||||||||||||||
Money market funds |
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||
Level 2 securities: | |||||||||||||||||||||||||||||||||||||||||||||||
Time Deposits
(1)
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||
Government securities
(2)
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||||||||||
As of December 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||
Amortized Cost | Gross Unrealized Gains | Gross Unrealized Losses | Estimated Fair Value | Cash and cash equivalents | Short-term investments | Other Current Assets | Non-current Assets | ||||||||||||||||||||||||||||||||||||||||
(in thousands) | |||||||||||||||||||||||||||||||||||||||||||||||
Cash | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||||||||
Level 1 securities: | |||||||||||||||||||||||||||||||||||||||||||||||
Money market funds |
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||
Level 2 securities: | |||||||||||||||||||||||||||||||||||||||||||||||
Time Deposits
(1)
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||
Government securities
(2)
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
As of | |||||||||||
March 31,
2025 |
December 31,
2024 |
||||||||||
(in thousands) | |||||||||||
Licensed content, net
|
$ |
|
$ |
|
|||||||
Produced content, net
|
|||||||||||
Released, less amortization
|
|
|
|||||||||
In production
|
|
|
|||||||||
In development and pre-production
|
|
|
|||||||||
|
|
||||||||||
|
|||||||||||
Content assets, net
|
$ |
|
$ |
|
|||||||
Three Months Ended | |||||||||||||||||||||||
March 31,
2025 |
March 31,
2024 |
||||||||||||||||||||||
(in thousands) | |||||||||||||||||||||||
Licensed content | $ |
|
$ |
|
|||||||||||||||||||
Produced content |
|
|
|||||||||||||||||||||
Total | $ |
|
$ |
|
As of | ||||||||||||||||||||
March 31,
2025 |
December 31,
2024 |
Estimated Useful Lives | ||||||||||||||||||
(in thousands) | ||||||||||||||||||||
Land
|
$ |
|
$ |
|
||||||||||||||||
Buildings and improvements
|
|
|
|
|||||||||||||||||
Leasehold improvements
|
|
|
Over life of lease | |||||||||||||||||
Furniture and fixtures
|
|
|
|
|||||||||||||||||
Information technology
|
|
|
|
|||||||||||||||||
Corporate aircraft
|
|
|
|
|||||||||||||||||
Machinery and equipment
|
|
|
|
|||||||||||||||||
Capital work-in-progress
|
|
|
||||||||||||||||||
Property and equipment, gross
|
|
|
||||||||||||||||||
Less: Accumulated depreciation
|
(
|
(
|
||||||||||||||||||
Property and equipment, net
|
$ |
|
$ |
|
Three Months Ended | |||||||||||||||||||||||
March 31,
2025 |
March 31,
2024 |
||||||||||||||||||||||
(in thousands) | |||||||||||||||||||||||
Cash paid for operating lease liabilities | $ |
|
$ |
|
|||||||||||||||||||
Right-of-use assets obtained in exchange for new operating lease obligations |
|
|
As of | |||||||||||
March 31,
2025 |
December 31,
2024 |
||||||||||
(in thousands) | |||||||||||
Operating lease right-of-use assets, net | $ |
|
$ |
|
|||||||
Current operating lease liabilities |
|
|
|||||||||
Non-current operating lease liabilities |
|
|
|||||||||
Total operating lease liabilities | $ |
|
$ |
|
As of | ||||||||||||||
March 31,
2025 |
December 31,
2024 |
|||||||||||||
(in thousands) | ||||||||||||||
Trade receivables
|
$ |
|
$ |
|
||||||||||
Prepaid expenses
|
|
|
||||||||||||
Other
|
|
|
||||||||||||
Total other current assets
|
$ |
|
$ |
|
Principal Amount at Par | Level 2 Fair Value as of | |||||||||||||||||||||||||||||||||||||
March 31,
2025 |
December 31,
2024 |
Issuance Date | Maturity |
March 31,
2025 |
December 31,
2024 |
|||||||||||||||||||||||||||||||||
(in millions) | (in millions) | |||||||||||||||||||||||||||||||||||||
|
$ |
|
$ |
|
February 2015 | February 2025 | $ |
|
$ |
|
||||||||||||||||||||||||||||
|
|
|
April 2020 | June 2025 |
|
|
||||||||||||||||||||||||||||||||
|
|
|
April 2020 | June 2025 |
|
|
||||||||||||||||||||||||||||||||
|
|
|
October 2016 | November 2026 |
|
|
||||||||||||||||||||||||||||||||
|
|
|
May 2017 | May 2027 |
|
|
||||||||||||||||||||||||||||||||
|
|
|
October 2017 | April 2028 |
|
|
||||||||||||||||||||||||||||||||
|
|
|
April 2018 | November 2028 |
|
|
||||||||||||||||||||||||||||||||
|
|
|
October 2018 | May 2029 |
|
|
||||||||||||||||||||||||||||||||
|
|
|
October 2018 | May 2029 |
|
|
||||||||||||||||||||||||||||||||
|
|
|
April 2019 | November 2029 |
|
|
||||||||||||||||||||||||||||||||
|
|
|
April 2019 | November 2029 |
|
|
||||||||||||||||||||||||||||||||
|
|
|
October 2019 | June 2030 |
|
|
||||||||||||||||||||||||||||||||
|
|
|
October 2019 | June 2030 |
|
|
||||||||||||||||||||||||||||||||
|
|
|
August 2024 | August 2034 |
|
|
||||||||||||||||||||||||||||||||
|
|
|
August 2024 | August 2054 |
|
|
||||||||||||||||||||||||||||||||
$ |
|
$ |
|
$ |
|
$ |
|
As of | |||||||||||
March 31,
2025 |
December 31,
2024 |
||||||||||
(in thousands) | |||||||||||
Derivatives designated as hedging instruments:
|
|||||||||||
Foreign exchange contracts
|
|||||||||||
Cash flow hedges
|
$ |
|
$ |
|
|||||||
Fair value hedges
|
|
|
|||||||||
Derivatives not designated as hedging instruments:
|
|||||||||||
Foreign exchange contracts |
|
|
|||||||||
Total
|
$ |
|
$ |
|
As of March 31, 2025 | |||||||||||||||||||||||
Derivative Assets | Derivative Liabilities | ||||||||||||||||||||||
Other current assets | Other non-current assets | Accrued expenses and other liabilities | Other non-current liabilities | ||||||||||||||||||||
(in thousands) | |||||||||||||||||||||||
Derivatives designated as hedging instruments: | |||||||||||||||||||||||
Foreign exchange contracts | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Derivatives not designated as hedging instruments: | |||||||||||||||||||||||
Foreign exchange contracts |
|
|
|
|
|||||||||||||||||||
Total | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
As of December 31, 2024 | |||||||||||||||||||||||
Derivative Assets | Derivative Liabilities | ||||||||||||||||||||||
Other current assets | Other non-current assets | Accrued expenses and other liabilities | Other non-current liabilities | ||||||||||||||||||||
(in thousands) | |||||||||||||||||||||||
Derivatives designated as hedging instruments: | |||||||||||||||||||||||
Foreign exchange contracts | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Derivatives not designated as hedging instruments: | |||||||||||||||||||||||
Foreign exchange contracts |
|
|
|
|
|||||||||||||||||||
Total | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
As of March 31, 2025 | |||||||||||||||||||||||||||||||||||
Gross Amount Not Offset in the Consolidated Balance Sheets | |||||||||||||||||||||||||||||||||||
Gross Amount Recognized in the Consolidated Balance Sheets | Gross Amount Offset in the Consolidated Balance Sheets | Net Amount Presented in the Consolidated Balance Sheets | Financial Instruments | Collateral Received and Posted | Net Amount | ||||||||||||||||||||||||||||||
(in thousands) | |||||||||||||||||||||||||||||||||||
Derivative assets | $ |
|
$ |
|
$ |
|
$ |
(
|
$ |
|
$ |
|
|||||||||||||||||||||||
Derivative liabilities |
|
|
|
(
|
|
|
|||||||||||||||||||||||||||||
As of December 31, 2024 | |||||||||||||||||||||||||||||||||||
Gross Amount Not Offset in the Consolidated Balance Sheets | |||||||||||||||||||||||||||||||||||
Gross Amount Recognized in the Consolidated Balance Sheets | Gross Amount Offset in the Consolidated Balance Sheets | Net Amount Presented in the Consolidated Balance Sheets | Financial Instruments | Collateral Received and Posted | Net Amount | ||||||||||||||||||||||||||||||
(in thousands) | |||||||||||||||||||||||||||||||||||
Derivative assets | $ |
|
$ |
|
$ |
|
$ |
(
|
$ |
(
|
$ |
|
|||||||||||||||||||||||
Derivative liabilities |
|
|
|
(
|
|
|
|||||||||||||||||||||||||||||
Three Months Ended | |||||||||||||||||||||||
March 31,
2025 |
March 31,
2024 |
||||||||||||||||||||||
(in thousands) | |||||||||||||||||||||||
Cash flow hedges: | |||||||||||||||||||||||
Foreign exchange contracts | |||||||||||||||||||||||
Amount included in the assessment of effectiveness | $ |
(
|
$ |
|
|||||||||||||||||||
Fair value hedges: | |||||||||||||||||||||||
Foreign exchange contracts | |||||||||||||||||||||||
Amount excluded from the assessment of effectiveness |
(
|
|
|||||||||||||||||||||
Net investment hedges: | |||||||||||||||||||||||
Foreign currency-denominated debt | |||||||||||||||||||||||
Amount included in the assessment of effectiveness |
(
|
|
|||||||||||||||||||||
Total | $ |
(
|
$ |
|
Three Months Ended | |||||||||||||||||
March 31, 2025 | |||||||||||||||||
Revenues | Cost of Revenues | Interest and other income (expense) | |||||||||||||||
(in thousands) | |||||||||||||||||
Total amounts presented in the Consolidated Statements of Operations | $ |
|
$ |
|
$ |
|
|||||||||||
Gains (losses) on derivatives in cash flow hedging relationship | |||||||||||||||||
Foreign exchange contracts | |||||||||||||||||
Amount of gains (losses) reclassified from AOCI |
|
(
|
|
||||||||||||||
Gains (losses) on derivatives in fair value hedging relationship | |||||||||||||||||
Foreign exchange contracts | |||||||||||||||||
Hedged items |
|
|
(
|
||||||||||||||
Derivatives designated as hedging instruments |
|
|
|
||||||||||||||
Amount excluded from assessment of effectiveness and recognized in earnings based on amortization approach |
|
|
(
|
||||||||||||||
Losses on derivatives not designated as hedging instruments | |||||||||||||||||
Foreign exchange contracts |
|
|
(
|
Three Months Ended | |||||||||||||||||
March 31, 2024 | |||||||||||||||||
Revenues | Cost of Revenues | Interest and other income (expense) | |||||||||||||||
(in thousands) | |||||||||||||||||
Total amounts presented in the Consolidated Statements of Operations | $ |
|
$ |
|
$ |
|
|||||||||||
Gains (losses) on derivatives in cash flow hedging relationship | |||||||||||||||||
Foreign exchange contracts | |||||||||||||||||
Amount of gains (losses) reclassified from AOCI |
(
|
|
|
||||||||||||||
Gains (losses) on derivatives in fair value hedging relationship | |||||||||||||||||
Foreign exchange contracts | |||||||||||||||||
Hedged items |
|
|
|
||||||||||||||
Derivatives designated as hedging instruments |
|
|
|
||||||||||||||
Amount excluded from assessment of effectiveness and recognized in earnings based on amortization approach |
|
|
|
||||||||||||||
Gains on derivatives not designated as hedging instruments | |||||||||||||||||
Foreign exchange contracts |
|
|
|
As of | |||||||||||
March 31,
2025 |
December 31,
2024 |
||||||||||
(in thousands) | |||||||||||
Less than one year
|
$ |
|
$ |
|
|||||||
Due after one year and through three years
|
|
|
|||||||||
Due after three years and through five years
|
|
|
|||||||||
Due after five years
|
|
|
|||||||||
Total content obligations
|
$ |
|
$ |
|
Options Outstanding | |||||||||||||||||||||||
Number of
Shares |
Weighted-
Average Exercise Price (per share) |
||||||||||||||||||||||
Balances as of December 31, 2024 |
|
$ |
|
||||||||||||||||||||
Granted
|
|
|
|||||||||||||||||||||
Exercised
|
(
|
|
|||||||||||||||||||||
Expired
|
(
|
|
|||||||||||||||||||||
Balances as of March 31, 2025 |
|
$ |
|
||||||||||||||||||||
Vested and exercisable as of March 31, 2025 |
|
$ |
|
Unvested Restricted Stock Units | |||||||||||
Number of
Shares |
Weighted-
Average Grant-Date Fair Value (per share) |
||||||||||
Balances as of December 31, 2024 |
|
$ |
|
||||||||
Granted
(1)
|
|
|
|||||||||
Vested
(1)
|
(
|
|
|||||||||
Forfeited
|
|
|
|||||||||
Balances as of March 31, 2025 |
|
$ |
|
Foreign Currency Translation
Adjustments |
Net Investment Hedge Gains (Losses) | Change in Unrealized Gains (Losses) on Cash Flow Hedges | Change in Unrealized Gains (Losses) on Excluded Component of Fair Value Hedges |
Change in Unrealized Gains (Losses)
on AFS Securities |
Tax (Expense) Benefit | Total | |||||||||||||||||||||||||||||||||||
(in thousands) | |||||||||||||||||||||||||||||||||||||||||
Balances as of December 31, 2024 | $ |
(
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
(
|
$ |
|
|||||||||||||||||||||||||||
Other comprehensive income (loss) before reclassifications
|
|
(
|
(
|
(
|
(
|
|
(
|
||||||||||||||||||||||||||||||||||
Amounts reclassified from accumulated other comprehensive income (loss)
|
|
|
(
|
|
(
|
|
(
|
||||||||||||||||||||||||||||||||||
Net change in accumulated other comprehensive income (loss) |
|
(
|
(
|
(
|
(
|
|
(
|
||||||||||||||||||||||||||||||||||
Balances as of March 31, 2025 | $ |
(
|
$ |
(
|
$ |
|
$ |
|
$ |
|
$ |
(
|
$ |
(
|
Foreign Currency Translation
Adjustments |
Net Investment Hedge Gains (Losses) | Change in Unrealized Gains (Losses) on Cash Flow Hedges | Change in Unrealized Gains (Losses) on Excluded Component of Fair Value Hedges |
Change in Unrealized Gains (Losses)
on AFS Securities |
Tax (Expense) Benefit | Total | |||||||||||||||||||||||||||||||||||
(in thousands) | |||||||||||||||||||||||||||||||||||||||||
Balances as of December 31, 2023 | $ |
(
|
$ |
|
$ |
(
|
$ |
|
$ |
|
$ |
|
$ |
(
|
|||||||||||||||||||||||||||
Other comprehensive income (loss) before reclassifications
|
(
|
|
|
|
|
(
|
|
||||||||||||||||||||||||||||||||||
Amounts reclassified from accumulated other comprehensive income (loss)
|
|
|
|
|
|
(
|
|
||||||||||||||||||||||||||||||||||
Net change in accumulated other comprehensive income (loss)
|
(
|
|
|
|
|
(
|
|
||||||||||||||||||||||||||||||||||
Balances as of March 31, 2024 | $ |
(
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
(
|
$ |
(
|
Three Months Ended | |||||||||||||||||||||||||||||||||||||||||
March 31, 2025 | |||||||||||||||||||||||||||||||||||||||||
Revenues | Cost of Revenues | Interest and other income (expense) | Provision for Income Taxes | Total Reclassifications | |||||||||||||||||||||||||||||||||||||
(in thousands) | |||||||||||||||||||||||||||||||||||||||||
Gains (losses) on available-for-sale securities | |||||||||||||||||||||||||||||||||||||||||
Amount of gains (losses) reclassified from AOCI | $ |
|
$ |
|
$ |
|
$ |
(
|
$ |
|
|||||||||||||||||||||||||||||||
Gains (losses) on derivatives in cash flow hedging relationship | |||||||||||||||||||||||||||||||||||||||||
Foreign exchange contracts | |||||||||||||||||||||||||||||||||||||||||
Amount of gains (losses) reclassified from AOCI |
|
(
|
|
(
|
|
||||||||||||||||||||||||||||||||||||
Gains (losses) on derivatives in fair value hedging relationship | |||||||||||||||||||||||||||||||||||||||||
Foreign exchange contracts | |||||||||||||||||||||||||||||||||||||||||
Amount excluded from assessment of effectiveness and recognized in earnings based on amortization approach |
|
|
(
|
|
(
|
||||||||||||||||||||||||||||||||||||
Total | $ |
|
$ |
(
|
$ |
(
|
$ |
(
|
$ |
|
Three Months Ended | |||||||||||||||||||||||||||||||||||||||||
March 31, 2024 | |||||||||||||||||||||||||||||||||||||||||
Revenues | Cost of Revenues | Interest and other income (expense) | Provision for Income Taxes | Total Reclassifications | |||||||||||||||||||||||||||||||||||||
(in thousands) | |||||||||||||||||||||||||||||||||||||||||
Gains (losses) on available-for-sale securities | |||||||||||||||||||||||||||||||||||||||||
Amount of gains (losses) reclassified from AOCI | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||||||||
Gains (losses) on derivatives in cash flow hedging relationship | |||||||||||||||||||||||||||||||||||||||||
Foreign exchange contracts | |||||||||||||||||||||||||||||||||||||||||
Amount of gains (losses) reclassified from AOCI |
(
|
|
|
|
(
|
||||||||||||||||||||||||||||||||||||
Gains (losses) on derivatives in fair value hedging relationship | |||||||||||||||||||||||||||||||||||||||||
Foreign exchange contracts | |||||||||||||||||||||||||||||||||||||||||
Amount excluded from assessment of effectiveness and recognized in earnings based on amortization approach |
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
Total | $ |
(
|
$ |
|
$ |
|
$ |
|
$ |
(
|
Three Months Ended | ||||||||||||||||||||||||||
March 31,
2025 |
March 31,
2024 |
|||||||||||||||||||||||||
(in thousands, except percentages) | ||||||||||||||||||||||||||
Provision for income taxes | $ |
|
$ |
|
||||||||||||||||||||||
Effective tax rate |
|
% |
|
% |
Three Months Ended | |||||||||||||||||
March 31,
2025 |
March 31,
2024 |
||||||||||||||||
(in thousands) | |||||||||||||||||
Revenues | $ |
|
$ |
|
|||||||||||||
Less: | |||||||||||||||||
Content amortization |
|
|
|||||||||||||||
Other cost of revenues |
|
|
|||||||||||||||
Sales and marketing |
|
|
|||||||||||||||
Technology and development |
|
|
|||||||||||||||
General and administrative |
|
|
|||||||||||||||
Operating income |
|
|
|||||||||||||||
Operating margin |
|
% |
|
% | |||||||||||||
Other income (expense) | |||||||||||||||||
Interest expense |
(
|
(
|
|||||||||||||||
Interest and other income (expense)
(1)
|
|
|
|||||||||||||||
Income before income taxes |
|
|
|||||||||||||||
Provision for income taxes |
(
|
(
|
|||||||||||||||
Net income | $ |
|
$ |
|
As of | |||||||||||
March 31,
2025 |
December 31,
2024 |
||||||||||
(in thousands) | |||||||||||
United States | $ |
|
$ |
|
|||||||
International |
|
|
Three Months Ended | Change | ||||||||||||||||||||||
March 31,
2025 |
March 31,
2024 |
Q1'25 vs. Q1'24 | |||||||||||||||||||||
(in thousands, except percentages) | |||||||||||||||||||||||
Financial Results: | |||||||||||||||||||||||
Revenues | $ | 10,542,801 | $ | 9,370,440 | $ | 1,172,361 | 13 | % | |||||||||||||||
Constant currency change in revenues
(2)
|
16 | % | |||||||||||||||||||||
Operating income | $ | 3,346,999 | $ | 2,632,534 | $ | 714,465 | 27 | % | |||||||||||||||
Operating margin | 31.7 | % | 28.1 | % | 3.6 | % | |||||||||||||||||
Net income
|
$ | 2,890,351 | $ | 2,332,209 | $ | 558,142 | 24 | % |
Three Months Ended | Change | |||||||||||||||||||||||||
March 31,
2025 |
March 31,
2024 |
Q1'25 vs. Q1'24 | ||||||||||||||||||||||||
(in thousands, except percentages) | ||||||||||||||||||||||||||
Revenues
|
$ | 10,542,801 | $ | 9,370,440 | $ | 1,172,361 | 13 | % | ||||||||||||||||||
Three Months Ended | Change | |||||||||||||||||||||||||
March 31,
2025 |
March 31,
2024 |
Q1'25 vs. Q1'24 | ||||||||||||||||||||||||
(in thousands, except percentages) | ||||||||||||||||||||||||||
United States and Canada (UCAN) | $ | 4,617,098 | $ | 4,224,315 | $ | 392,783 | 9 | % | ||||||||||||||||||
Europe, Middle East, and Africa (EMEA) | 3,404,676 | 2,958,193 | 446,483 | 15 | % | |||||||||||||||||||||
Latin America (LATAM) | 1,261,934 | 1,165,008 | 96,926 | 8 | % | |||||||||||||||||||||
Asia-Pacific (APAC) | 1,259,093 | 1,022,924 | 236,169 | 23 | % | |||||||||||||||||||||
Total Revenues | $ | 10,542,801 | $ | 9,370,440 | $ | 1,172,361 | 13 | % | ||||||||||||||||||
Three Months Ended | Three Months Ended | Change | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
March 31,
2025 |
March 31,
2024 |
Q1'25 vs. Q1'24 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
As Reported | Constant Currency Adjustment | Hedging (Gains) Losses Included in Revenues | Constant Currency Revenues | As Reported | Hedging (Gains) Losses Included in Revenues |
Revenues
Less Hedging Impact |
Reported Change | Constant Currency Change | ||||||||||||||||||||||||||||||||||||||||||||||||
(in thousands, except percentages) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
UCAN | $ | 4,617,098 | $ | 23,338 | $ | (14,552) | $ | 4,625,884 | $ | 4,224,315 | $ | 831 | $ | 4,225,146 | 9 | % | 9 | % | ||||||||||||||||||||||||||||||||||||||
EMEA | 3,404,676 | 146,975 | (105,225) | 3,446,426 | 2,958,193 | 4,687 | 2,962,880 | 15 | % | 16 | % | |||||||||||||||||||||||||||||||||||||||||||||
LATAM | 1,261,934 | 243,068 | (13,936) | 1,491,066 | 1,165,008 | 6,266 | 1,171,274 | 8 | % | 27 | % | |||||||||||||||||||||||||||||||||||||||||||||
APAC | 1,259,093 | 62,243 | (31,083) | 1,290,253 | 1,022,924 | (543) | 1,022,381 | 23 | % | 26 | % | |||||||||||||||||||||||||||||||||||||||||||||
Total Revenues | $ | 10,542,801 | $ | 475,624 | $ | (164,796) | $ | 10,853,629 | $ | 9,370,440 | $ | 11,241 | $ | 9,381,681 | 13 | % | 16 | % |
Three Months Ended | Change | ||||||||||||||||||||||
March 31,
2025 |
March 31,
2024 |
Q1'25 vs. Q1'24 | |||||||||||||||||||||
(in thousands, except percentages) | |||||||||||||||||||||||
Cost of revenues
|
$ | 5,263,147 | $ | 4,977,073 | $ | 286,074 | 6 | % | |||||||||||||||
As a percentage of revenues
|
50 | % | 53 | % |
Three Months Ended | Change | ||||||||||||||||||||||
March 31,
2025 |
March 31,
2024 |
Q1'25 vs. Q1'24 | |||||||||||||||||||||
(in thousands, except percentages) | |||||||||||||||||||||||
Sales and marketing | $ | 688,370 | $ | 654,340 | $ | 34,030 | 5 | % | |||||||||||||||
As a percentage of revenues
|
7 | % | 7 | % |
Three Months Ended | Change | ||||||||||||||||||||||
March 31,
2025 |
March 31,
2024 |
Q1'25 vs. Q1'24 | |||||||||||||||||||||
(in thousands, except percentages) | |||||||||||||||||||||||
Technology and development
|
$ | 822,823 | $ | 702,473 | $ | 120,350 | 17 | % | |||||||||||||||
As a percentage of revenues
|
8 | % | 7 | % |
Three Months Ended | Change | ||||||||||||||||||||||
March 31,
2025 |
March 31,
2024 |
Q1'25 vs. Q1'24 | |||||||||||||||||||||
(in thousands, except percentages) | |||||||||||||||||||||||
General and administrative
|
$ | 421,462 | $ | 404,020 | $ | 17,442 | 4 | % | |||||||||||||||
As a percentage of revenues
|
4 | % | 4 | % |
Three Months Ended | Change | |||||||||||||||||||||||||
March 31,
2025 |
March 31,
2024 |
Q1'25 vs. Q1'24 | ||||||||||||||||||||||||
(in thousands, except percentages) | ||||||||||||||||||||||||||
Interest expense | $ | 184,172 | $ | 173,314 | $ | 10,858 | 6 | % | ||||||||||||||||||
As a percentage of revenues | 2 | % | 2 | % |
Three Months Ended | Change | |||||||||||||||||||||||||
March 31,
2025 |
March 31,
2024 |
Q1'25 vs. Q1'24 | ||||||||||||||||||||||||
(in thousands, except percentages) | ||||||||||||||||||||||||||
Interest and other income (expense) | $ | 50,899 | $ | 155,359 | $ | (104,460) | (67) | % | ||||||||||||||||||
As a percentage of revenues | — | % | 2 | % |
Three Months Ended | Change | |||||||||||||||||||||||||
March 31,
2025 |
March 31,
2024 |
Q1'25 vs. Q1'24 | ||||||||||||||||||||||||
(in thousands, except percentages) | ||||||||||||||||||||||||||
Provision for income taxes | $ | 323,375 | $ | 282,370 | $ | 41,005 | 15 | % | ||||||||||||||||||
Effective tax rate | 10 | % | 11 | % |
As of | Change | ||||||||||||||||||||||
March 31,
2025 |
December 31,
2024 |
March 31, 2025 vs. December 31, 2024 | |||||||||||||||||||||
(in thousands, except percentages) | |||||||||||||||||||||||
Cash, cash equivalents, restricted cash and short-term investments | $ | 8,375,170 | $ | 9,586,343 | $ | (1,211,173) | (13) | % | |||||||||||||||
Short-term and long-term debt | 15,016,918 | 15,582,804 | (565,886) | (4) | % |
Payments due by Period | ||||||||||||||||||||
Contractual obligations (in thousands): | Total | Next 12 Months | Beyond 12 Months | |||||||||||||||||
Content obligations
(1)
|
$ | 21,790,643 | $ | 10,977,295 | $ | 10,813,348 | ||||||||||||||
Debt
(2)
|
19,242,462 | 1,697,194 | 17,545,268 | |||||||||||||||||
Operating lease obligations
(3)
|
2,833,759 | 530,875 | 2,302,884 | |||||||||||||||||
Total
|
$ | 43,866,864 | $ | 13,205,364 | $ | 30,661,500 |
Three Months Ended | Change | ||||||||||||||||||||||
March 31,
2025 |
March 31,
2024 |
Q1'25 vs. Q1'24 | |||||||||||||||||||||
(in thousands, except percentages) | |||||||||||||||||||||||
Net cash provided by operating activities
|
$ | 2,789,199 | $ | 2,212,522 | $ | 576,677 | 26 | % | |||||||||||||||
Net cash provided by (used in) investing activities
|
485,662 | (75,714) | 561,376 | 741 | % | ||||||||||||||||||
Net cash used in financing activities | (4,028,316) | (2,132,944) | 1,895,372 | 89 | % |
Period |
Total Number of Shares Purchased
(1)
|
Average Price Paid per Share
(2)
|
Total Number of Shares Purchased as Part of Publicly Announced Programs
(1)
|
Approximate Dollar Value of Shares that May Yet Be Purchased Under the Program
(1)
|
||||||||||||||||||||||
(in thousands) | ||||||||||||||||||||||||||
January 1 - 31, 2025 | 703,147 | $ | 866.91 | 703,147 | $ | 16,534,209 | ||||||||||||||||||||
February 1 - 28, 2025 | 1,354,600 | $ | 1,007.46 | 1,354,600 | $ | 15,169,503 | ||||||||||||||||||||
March 1 - 31, 2025 | 1,656,081 | $ | 943.27 | 1,656,081 | $ | 13,607,380 | ||||||||||||||||||||
Total
|
3,713,828 | 3,713,828 |
(1) In September 2023, the Company’s Board of Directors authorized the repurchase of up to $10 billion of its common stock, with no expiration date, and in December 2024, the Board of Directors increased the share repurchase authorization by an additional $15 billion, also with no expiration date. For further information regarding stock repurchase activity, see Note 9 Stockholders’ Equity to the consolidated financial statements in this Quarterly Report.
|
||
(2) Average price paid per share includes costs associated with the repurchases but excludes the 1% excise tax on stock repurchases imposed by the Inflation Reduction Act of 2022. |
Name | Title | Action | Date Adopted | Expiration Date | Aggregate # of Securities to be Purchased/Sold | |||||||||||||||||||||||||||
|
|
|
|
|
|
|||||||||||||||||||||||||||
|
|
|
|
|
|
|||||||||||||||||||||||||||
|
|
|
|
|
|
|||||||||||||||||||||||||||
|
|
|
|
|
|
|||||||||||||||||||||||||||
|
|
|
|
|
|
(1) Jay Hoag, a member of the Board of Directors, trusts for which he serves as a trustee and a partnership for which he serves as the sole general partner and limited partner, entered into a pre-arranged stock trading plan pursuant to Rule 10b5-1 on January 28, 2025. The plan provides for the potential sale of up to
|
||
(2) Ann Mather, a member of the Board of Directors, entered into a pre-arranged stock trading plan pursuant to Rule 10b5-1 on February 7, 2025. Ms. Mather's plan provides for the potential exercise of vested stock options and the associated sale of up to
|
||
(3) Strive Masiyiwa, a member of the Board of Directors, entered into a pre-arranged stock trading plan pursuant to Rule 10b5-1 on February 10, 2025. Mr. Masiyiwa's plan provides for the potential exercise of vested stock options and the associated sale of up to
|
||
(4) Brad Smith, a member of the Board of Directors, entered into a pre-arranged stock trading plan pursuant to Rule 10b5-1 on February 10, 2025. Mr. Smith's plan provides for the potential exercise of vested stock options and the associated sale of up to
|
||
(5) Leslie Kilgore, a member of the Board of Directors, entered into a pre-arranged stock trading plan pursuant to Rule 10b5-1 on January 22, 2025. Ms. Kilgore's plan provides for the potential exercise of vested stock options and the associated sale of up to
|
Exhibit Number | Exhibit Description |
Incorporated by Reference
|
Filed
Herewith |
|||||||||||||||||||||||||||||||||||
Form | File No. | Exhibit | Filing Date | |||||||||||||||||||||||||||||||||||
8-K | 001-35727 | 3.1 | June 8, 2022 | |||||||||||||||||||||||||||||||||||
8-K | 001-35727 | 3.2 | February 24, 2023 | |||||||||||||||||||||||||||||||||||
X | ||||||||||||||||||||||||||||||||||||||
X | ||||||||||||||||||||||||||||||||||||||
X | ||||||||||||||||||||||||||||||||||||||
X | ||||||||||||||||||||||||||||||||||||||
101 | The following financial statements from the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, formatted in Inline XBRL: (i) Consolidated Statements of Operations, (ii) Consolidated Statements of Comprehensive Income, (iii) Consolidated Statements of Cash Flows, (iv) Consolidated Balance Sheets, (v) Consolidated Statements of Stockholders' Equity and (vi) Notes to Consolidated Financial Statements, tagged as blocks of text and including detailed tags | X | ||||||||||||||||||||||||||||||||||||
104 | The cover page from the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, formatted in Inline XBRL | X |
NETFLIX, INC.
|
|||||||||||
Dated: | April 18, 2025 | By: | /s/ Ted Sarandos | ||||||||
Ted Sarandos
Co-Chief Executive Officer (Principal executive officer) |
|||||||||||
Dated: | April 18, 2025 | By: | /s/ Greg Peters | ||||||||
Greg Peters
Co-Chief Executive Officer (Principal executive officer) |
|||||||||||
Dated: | April 18, 2025 | By: | /s/ Jeffrey Karbowski | ||||||||
Jeffrey Karbowski
Chief Accounting Officer (Principal accounting officer) |
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
---|
DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
---|
No information found
Customers
Customer name | Ticker |
---|---|
Amazon.com, Inc. | AMZN |
Micron Technology, Inc. | MU |
Microsoft Corporation | MSFT |
Oracle Corporation | ORCL |
No Suppliers Found
Price
Yield
Owner | Position | Direct Shares | Indirect Shares |
---|